Broad spectrum vasopressors: a new approach to the initial management of septic shock?

by Lakhmir S. Chawla, Marlies Ostermann, Lui Forni, George F. Tidmarsh
Published 2019-04-01

Bridging the gap between basic and applied biology: towards preclinical translation

by Ross L. Cagan, Monica J. Justice, George F. Tidmarsh
Published 2013-05-01

Angiotensin converting enzyme defects in shock: implications for future therapy

by Lakhmir S. Chawla, Steve Chen, Rinaldo Bellomo, George F. Tidmarsh
Published 2018-10-01

A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo

by W. Steve Ammons, Jin-Wei Wang, Zhijian Yang, George F. Tidmarsh, Robert M. Hoffman
Published 2007-08-01

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

by Kealy R. Ham, David W. Boldt, Michael T. McCurdy, Laurence W. Busse, Raphael Favory, Michelle N. Gong, Ashish K. Khanna, Stefan N. Chock, Feng Zeng, Lakhmir S. Chawla, George F. Tidmarsh, Marlies Ostermann
Published 2019-06-01

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock

by Rinaldo Bellomo, Richard G. Wunderink, Harold Szerlip, Shane W. English, Laurence W. Busse, Adam M. Deane, Ashish K. Khanna, Michael T. McCurdy, Marlies Ostermann, Paul J. Young, Damian R. Handisides, Lakhmir S. Chawla, George F. Tidmarsh, Timothy E. Albertson
Published 2020-02-01